{"nctId":"NCT01561079","briefTitle":"Fetal and Infant Effects of Maternal Buprenorphine Treatment","startDateStruct":{"date":"2012-02"},"conditions":["Neonatal Abstinence Syndrome"],"count":127,"armGroups":[{"label":"Maternal buprenorphine treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine"]}],"interventions":[{"name":"Buprenorphine","otherNames":["Subutex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Current opioid dependence as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM) IV-R criteria\n* 18-40 years of age with uncomplicated singleton pregnancies\n* Accurate gestational age dating verified by ultrasound\n* Gestation of less than 34 weeks\n* Stabilization on buprenorphine for one week prior to study procedures\n\nExclusion Criteria:\n\n* Complications of pregnancy, including gestational diabetes, polyhydramnios, hypertension, placenta previa or significant risk of preterm delivery (i.e. incompetent cervix)\n* Evidence of fetal malformation detected by prenatal ultrasound\n* Significant general maternal health problems that can affect fetal functioning, including Type I or gestational diabetes, alterations in thyroid functioning, HIV infection or hypertension.\n* Significant maternal psychopathology that would preclude informed consent (i.e. schizophrenia)\n* Alcohol dependency per DSM IV R criteria (see ascertainment methods below)\n* Women stable on methadone maintenance (defined as more than 3 days of methadone dosing)\n* Women entering drug treatment reporting using \"street\" methadone (for more than 3 days)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Fetal Heart Rate","description":"Fetal heart rate in beats per minute at time of trough and peak maternal buprenorphine levels","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.7","spread":"5.8"},{"groupId":"OG001","value":"143.3","spread":"5.4"},{"groupId":"OG002","value":"138.6","spread":"6.0"},{"groupId":"OG003","value":"136.3","spread":"7.1"},{"groupId":"OG004","value":"143.9","spread":"6.4"},{"groupId":"OG005","value":"141.0","spread":"4.8"},{"groupId":"OG006","value":"135.4","spread":"6.3"},{"groupId":"OG007","value":"131.3","spread":"6.1"}]}]}]},{"type":"PRIMARY","title":"Fetal Heart Rate Variability","description":"Fetal heart rate variability at 24, 28, 32 and 36 weeks of gestation at times of trough and peak maternal buprenorphine levels","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"1.3"},{"groupId":"OG001","value":"6.7","spread":"1.9"},{"groupId":"OG002","value":"7.5","spread":"3.0"},{"groupId":"OG003","value":"7.9","spread":"2.1"},{"groupId":"OG004","value":"4.9","spread":"1.5"},{"groupId":"OG005","value":"7.3","spread":"1.8"},{"groupId":"OG006","value":"7.0","spread":"2.7"},{"groupId":"OG007","value":"6.3","spread":"2.1"}]}]}]},{"type":"PRIMARY","title":"Accelerations of Fetal Heart Rate","description":"Number of accelerations of fetal heart rate exhibited during the 60 minute recordings","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"1.59","spread":null},{"groupId":"OG002","value":"3.57","spread":null},{"groupId":"OG003","value":"5.28","spread":null},{"groupId":"OG004","value":"0.43","spread":null},{"groupId":"OG005","value":"2.12","spread":null},{"groupId":"OG006","value":"2.29","spread":null},{"groupId":"OG007","value":"2.25","spread":null}]}]}]},{"type":"PRIMARY","title":"Fetal Movement","description":"Fetal movement (number x duration of fetal movements) during the 60 minute recordings at times of trough and peak maternal buprenorphine levels","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1496.2","spread":"752.0"},{"groupId":"OG001","value":"1390.0","spread":"795.4"},{"groupId":"OG002","value":"1458.7","spread":"674.6"},{"groupId":"OG003","value":"1446.7","spread":"979.5"},{"groupId":"OG004","value":"1613.0","spread":"575.6"},{"groupId":"OG005","value":"1385.7","spread":"674.5"},{"groupId":"OG006","value":"1381.2","spread":"830.7"},{"groupId":"OG007","value":"1038.2","spread":"756.2"}]}]}]},{"type":"PRIMARY","title":"Fetal Movement - Fetal Heart Rate Coupling","description":"The integration between fetal movements and heart rate (FM-FHR coupling) was quantified as the proportion of time individual movements were associated with a change in FHR, using previously developed criteria. FM-FHR coupling reflects coactivation of the sympathetic and parasympathetic components of the autonomic nervous system.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.06"},{"groupId":"OG001","value":"0.21","spread":".07"},{"groupId":"OG002","value":"0.23","spread":"0.10"},{"groupId":"OG003","value":"0.25","spread":"0.11"},{"groupId":"OG004","value":"0.09","spread":"0.06"},{"groupId":"OG005","value":"0.20","spread":"0.09"},{"groupId":"OG006","value":"0.21","spread":"0.10"},{"groupId":"OG007","value":"0.20","spread":"0.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":49},"commonTop":["Cholestasis of pregnancy","cardiomegaly","chorioamnionitis","Fetal stress at delivery","nonreactive fetal tracing, fetal hear rate deceleration"]}}}